LIFR and breast cancer: Furthermore, we show that, in GC, LIF/LIFR signalling activates the Hippo kinase core MST1/2 and LATS1/2, thus inducing a phosphorylation cascade leading to the negative phosphorylation of oncogenic Hippo effectors YAP/TAZ and decreased oncogenic activity of the transcription factor TEAD, in accordance with what was observed in breast cancer [16,17].